PGPrecigen, Inc. PGEN · NASDAQ
$6.66 +4.23% (+$0.27)
- Market cap
- $2.38B
- Enterprise value
- $2.47B
- P/E
- -
- Forward P/E
- 43.8x
- PEG
- -
- P/S
- 27.8x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -27.8%
- Bruto marža
- 89.6%
- Neto marža
- -184.0%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 0.92
- Free float
- 45.9%
O podjetju
Precigen, Inc. (PGEN) is a biotechnology company focused on the development and commercialization of advanced therapeutic and diagnostic technologies. The company specializes in genome engineering and genetic manipulation, enabling the development of novel drugs and diagnostic tools for the treatment and detection of various diseases. Their technologies include CRISPR-Cas9 and other genome editing tools, gene therapy, immunotherapy, and genetic analysis-based diagnostic tests.
Sector
Healthcare
Industry
Biotechnology
CEO
Helen Sabzevari
Employees
160
Headquarters
Germantown
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke